According to present data X4 Pharmaceuticals… Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The Company sold 14,550,000 shares of common stock at $1.10 per share. The 1-20 reverse split was announced on Thursday, October 29th 2020. Fourth Quarter 2020 Financial Results Cash, Cash Equivalents & Restricted Cash: X4 had $80.7 million in cash, cash equivalents and restricted cash as of December 31, 2020. Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015 This is what happens when things don't go to according to plan. X4 Pharmaceuticals, Inc. (XFOR) Stock: Here’s Why It’s Down. We also anticipate initial data from our SCN Phase 1b trial in 2021.” Recent Highlights Received Fast Track and Rare Pediatric Designations (RPD) from the FDA for Mavorixafor for the treatment of WHIM Syndrome: These FDA designations further recognize WHIM as a serious condition with a clear unmet need in both adult and pediatric populations. Tonix Pharmaceuticals Holding Corp Falls Nearly 70% Today. Investors and Media: Daniel FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576 Mónica Rouco MolinaSenior Account ExecutiveLifeSci Communicationsmroucomolina@lifescicomms.com, Aemetis to Review Fourth Quarter and Year-End Financial Results on March 11, 2021, Alzheon to Present at H.C. Wainwright Global Life Sciences Conference on March 9, 2021, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Currency in USD, Trade prices are not sourced from all markets. (RTTNews) - Shares of Milestone Pharmaceuticals Inc. (MIST) plunged over 80% on Tuesday morning trade after the pharma company's trial on etripamil nasal spray failed. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) are down 35% at 1:41 p.m. EDT because the U.S. Food and Drug Administration issued a complete response letter for … Jacob Donnelly | June 3, 2016 Because a potential takeover fell through, Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) dropped. Net Loss: X4 reported net losses of $18.4 million and $62.1 million for the fourth quarter and full year ended December 31, 2020 as compared to net losses of $10.8 million and $52.8 million for the comparable periods in 2019, respectively. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Since then, XFOR shares … According to present data X4 Pharmaceuticals… Through the Fast Track program, X4 will be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, protocols and clinical data that would support mavorixafor’s potential approval for WHIM.Under the RPD program, a sponsor who receives an approval for a drug for a “rare pediatric disease” and a Fast Track designation may qualify for a voucher that can be redeemed to receive a priority review by the FDA for any subsequent marketing application for a different product. “As many companies did, we encountered a number of unexpected challenges in 2020, most notably the COVID-19 pandemic. Specifically, they have bought $0.00 in company stock and sold $20,160.00 in company stock. CNN Sans™ & © 2016 Cable News Network. The Tonix Pharmaceuticals Holding Corp. stock price gained 5.37% on the last trading day (Friday, 5th Mar 2021), rising from $0.97 to $1.02.During the day the stock … NEW YORK, NY / ACCESSWIRE / March 4, 2021 / X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 8:30 AM Eastern Time. Find the latest Tonix Pharmaceuticals Holding C (TNXP) stock quote, history, news and other vital information to help you with your stock trading and investing. The Investor Relations website contains information about X4 Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout Feb. 26, 2021 at 10:06 a.m. BOSTON (AP) _ X4 Pharmaceuticals, Inc. (XFOR) on Thursday reported a loss of $18.4 million in its fourth quarter. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biondvax Pharmaceuticals Ltd - ADR share forecasts, stock quote and buy / sell signals below.According to present data Biondvax Pharmaceuticals Ltd - ADR's BVXV shares and potentially … X4 continues to expect that its cash and cash equivalents will fund company operations into 2022. The drugmaker's shares are tanking … All the drama surrounding the U.S. healthcare industry these days has not put a damper on biotech stocks.The iShares Nasdaq Biotechnology ETF (IBB) is up nearly 20% year to date, and 11.6% since the beginning of June, with many of the top biotechs going into overdrive this summer. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of … Forward-looking statements include, without limitation, statements regarding the clinical development of mavorixafor and X4's other product candidates or programs, the potential benefits resulting from Fast Track and Rare Pediatric Disease designations, and the company’s cash runway. The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is … Following the completion of the call, a webcast replay of the conference call will be available on the website. X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 1053189. SPPI | Complete Spectrum Pharmaceuticals Inc. stock news by MarketWatch. The week couldn’t have gotten off to a worse start for investors of Acasti Pharma (ACST). Following the offering, the Company had an aggregate of 49,227,634 shares of common stock outstanding. ET to discuss these financial results and business highlights. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. Most stock quote data provided by BATS. (Tables Follow) X4 PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 2019License revenue$— $— $3,000 $— Operating expenses: Research and development12,298 7,065 41,932 30,163 General and administrative5,357 3,914 20,942 17,640 Loss on transfer of non-financial assets— (104) — 3,900 Total operating expenses17,655 10,875 62,874 51,703 Loss from operations(17,655) (10,875) (59,874) (51,703)Other income (expense), net(745) 38 (2,109) (1,104)Loss before provision for income taxes(18,400) (10,837) (61,983) (52,807)Provision for income taxes— — 148 — Net loss(18,400) (10,837) (62,131) (52,807)Adjustments related to convertible preferred stock— — — (592)Net loss attributable to common stockholders$(18,400) $(10,837) $(62,131) $(53,399)Net loss per share attributable to common stockholders- basic and diluted$(0.91) $(0.66) $(3.09) $(4.63)Weighted average common shares outstanding-basic and diluted20,174 16,466 20,077 11,530 X4 PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited) Year ended December 31, 2020 2019Net loss$(62,131) $(52,807)Adjustments to reconcile net loss to net cash used in operating activities7,376 7,988 Changes in operating assets and liabilities(4,063) (3,236)Net cash used in operating activities(58,818) (48,055)Net cash (used in) provided by investing activities(1,362) 27,232 Net cash provided by financing activities12,394 140,661 Impact of foreign exchange on cash, cash equivalents and restricted cash402 (250)Net (decrease) increase in cash, cash equivalents and restricted cash(47,384) 119,588 Cash, cash equivalents and restricted cash at beginning of period128,086 8,498 Cash, cash equivalents and restricted cash at end of period$80,702 $128,086 X4 PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited) December 31, 2020 December 31, 2019Current assets: Cash and cash equivalents$78,708 $126,184 Research and development incentive receivable917 1,998 Prepaid expenses and other current assets3,682 1,096 Total current assets83,307 129,278 Property and equipment, net1,237 403 Goodwill27,109 27,109 Right-of-use assets7,960 1,959 Other assets3,258 1,949 Total assets$122,871 $160,698 Current liabilities: Accounts payable$3,144 $2,088 Accrued expenses8,018 6,461 Current portion of lease liability786 898 Total current liabilities11,948 9,447 Long-term debt, including accretion, net of discount33,178 20,097 Lease liabilities4,484 1,918 Other liabilities462 16 Total liabilities50,072 31,478 Total stockholders' equity72,799 129,220 Total liabilities and stockholders' equity$122,871 $160,698 Contacts: Daniel Ferry (Investors)Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576 Mónica Rouco Molina (Media)Senior Account ExecutiveLifeSci Communicationsmroucomolina@lifescicomms.com. Jazz Pharmaceuticals plc has the potential to drop by 10 percent, and Vertex Pharmaceuticals Inc. could see declines of almost 11 percent. The company also provided an update on its lead product candidate, mavorixafor, a novel small molecule currently being evaluated in a Phase 3 clinical trial (4WHIM) for patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in two Phase 1b trials for patients with Waldenström’s macroglobulinemia (Waldenström’s) and Severe Congenital Neutropenia (SCN), respectively. Find the latest RESPIRERX PHARMACEUTICALS INC (RSPI) stock quote, history, news and other vital information to help you with your stock trading and investing. Approximately 6.0% of the shares of the stock are short sold. Buy X4 Pharmaceuticals Inc stock (XFOR). Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Find real-time XFOR - X4 Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Insiders buying/selling: X4 Pharmaceuticals Inc (NASDAQ:XFOR) In the past three months, X4 Pharmaceuticals insiders have sold more of their company’s stock than they have bought. The 1-15 reverse split was announced on Thursday, December 13th 2018. Wall Street Stock Market & Finance report, prediction for the future: You'll find the X4 Pharmaceuticals share forecasts, stock quote and buy / sell signals below. ET on Zacks.com Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. Biondvax Pharmaceuticals Ltd () Stock Market info Recommendations: Buy or sell Biondvax Pharmaceuticals Ltd - ADR stock? Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020, and in other filings X4 makes with the SEC from time to time. Such a voucher is transferable and may be sold.Mavorixafor was previously granted Breakthrough Therapy Designation by the FDA, as well as Orphan Drug status by the FDA and the European Commission for the treatment of WHIM syndrome. By targeting the CXCR4 pathway, our novel medicines are … Why Did GW Pharmaceuticals (GWPH) Drop 18% This Week? Why Vertex Pharmaceuticals Stock Is Slumping Today Investors are concerned about Vertex's pipeline after a rare miss in the clinic. Why Tonix Pharmaceuticals (TNXP) Stock Is Plummeting Today Shares of Tonix Pharmaceuticals (TNXP) plunged Monday after the company announced its … Pfizer, the pharmaceutical giant, said its clinical trial for a potential Coronavirus vaccine shows more than 90% efficacy in patients who receive a second dose after seven days. How did Intec Pharma's stock split work? GWPH – GWPH also substantially improved its bottom from the prior-year quarter. As of January 29th, there was short interest totaling 806,700 shares, a drop of 20.9% from the January 14th total of 1,020,000 shares. An investor that had 100 shares of Intec Pharma stock prior to the reverse split would have … © 2021 Verizon Media. Brian Feroldi (TMFTypeoh) Jan 11, … The company posted a net loss of $71.9 million which equates to $0.20 per share. Based on an average daily volume of 547,100 shares, the short-interest ratio is presently 1.5 days. Why Did Concordia Healthcare Corp. Drop Over 20% Yesterday? The Company will host a conference call and webcast on the same day at 8:30 a.m. But Teva Pharmaceuticals (TEVA) has gone in the opposite direction, and now TEVA stock is in complete free fall. All rights reserved. Find the latest X4 Pharmaceuticals, Inc. (XFOR) stock quote, history, news and other vital information to help you with your stock trading and investing. Sharp declines in each stock … All rights reserved. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 29th 2020. Why Did Intec Pharma Crash on Monday? Teva Pharmaceutical drops 16% after 44 states accuse drugmaker of conspiring to hike generic drug prices . View the latest X4 Pharmaceuticals Inc. (XFOR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Feb 27, 2020 GW Pharmaceuticals (GWPH) reported earnings at the close of trading on Tuesday. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. Stay up to date with X4 Pharmaceuticals Inc stock news. The results did not meet Wall Street expectations. Stock analysis for NeuroBo Pharmaceuticals Inc (NRBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. IHE has provided a … Disclaimer. ET to discuss these financial results and business highlights. “As many companies did, we encountered a number of unexpected challenges in 2020, most notably the COVID-19 pandemic. BOSTON (AP) _ X4 Pharmaceuticals, Inc. (XFOR) on Thursday reported a loss of $18.4 million in its fourth quarter. R&D expenses include $0.6 million and $2.3 million of certain non-cash expenses for the fourth quarter and fully year ended December 31, 2020, respectively. Today’s laggard could be a biotech stock to watch tomorrow. G&A expenses include $0.8 million and $3.1 million of certain non-cash expenses for the fourth quarter and full year ended December 31, 2020, respectively. Pharmaceutical stocks, as represented by the iShares U.S. Pharmaceuticals ETF , have underperformed the broader market over the past year. Jazz Pharmaceuticals plc has the potential to drop by 10 percent, and Vertex Pharmaceuticals Inc. could see declines of almost 11 percent. VRTX: Get the latest Vertex Pharmaceuticals stock price and detailed information including VRTX news, historical charts and realtime prices. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. X4 Pharmaceuticals, Inc. (XFOR) is trending down in the market in today’s trading session. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans or intentions. Prior to X4 he was the Senior Director of External Quality at Alnylam Pharmaceuticals, where he was a part of the team responsible for approval and launch of their first siRNA product. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. All Rights Reserved. The following presents a detailed X4 Pharmaceuticals stock price history for your review. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. The stock, focused on the biotech … Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference. Pharmaceutical stocks, as represented by the iShares U.S. Pharmaceuticals ETF , have underperformed the broader market over the past year. IHE has provided a total return of 16.3% over … See X4 Pharmaceuticals, Inc. (XFOR) Environment, Social and Governance Ratings to help you in your stock buying decisions. Wall Street Stock Market & Finance report, prediction for the future: You'll find the X4 Pharmaceuticals share forecasts, stock quote and buy / sell signals below. IBD’s coverage of the biotech stock news and pharma stocks today keeps you on top of these fast-moving companies. Published Mon, May 13 2019 12:26 PM EDT Updated Mon, May 13 … The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia. X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. “I think we can Any forward-looking statements in this press release are based on management's current expectations and beliefs. By Aaron Missere. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. Stocks of pharmaceutical companies are falling because investors are worried that the Trump administration’s war to rein in drug prices is just heating up—and that big pharma … All rights reserved. Factset: FactSet Research Systems Inc.2019. ET BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the fourth quarter and full year ended December 31, 2020. The results did … Only 4.90% of the stock of X4 Pharmaceuticals … By Margaret Patrick. X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. All times are ET. X4 Pharmaceuticals is a Massachusetts-based, clinical-stage biopharmaceutical company.It late 2018, it acquired publicly held Arsanis (). © 2020 Cable News Network. To help provide a sense of the short to long-term trend, included is an interactive X4 Pharmaceuticals stock chart … What happened. Volatile ride for Tonix Pharmaceuticals Holding Corp. stock price on Friday moving between $0.81 and $1.03 (Updated on March 05, 2021) Sell candidate since 2021-03-02 Loss -16.39% PDF . The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). Jul. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Throughout his … Diffusion Pharmaceuticals's stock reverse split before market open on Friday, December 14th 2018. For more information, please visit www.x4pharma.com. The Boston-based company said it had a loss of 91 cents per share. View real-time stock prices and stock quotes for a full financial overview. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 87 cents per share. Intec Pharma's stock reverse split on the morning of Friday, October 30th 2020. For more information, please visit www.x4pharma.com. NEW YORK, July 15, 2020 -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the. SYRS | Complete Syros Pharmaceuticals Inc. stock news by MarketWatch. The pharmaceutical market is expected to increase in value, meaning there are plenty of opportunities for investing in pharmaceutical stocks. Shares of the clinical-stage biotech Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) fell by as much as 77% in pre-market trading Tuesday morning. How did Diffusion Pharmaceuticals' stock split work? About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. Actinium Pharmaceuticals saw a drop in short interest during the month of January. Regeneron Pharmaceuticals, Inc. () Stock Market info Recommendations: Buy or sell Regeneron Pharmaceuticals stock? Sharp declines in each stock could … Eli Lilly (LLY) was down 4.6% in morning trading, while Pfizer (PFE) was down 3.4%, and Merck & Co. (MRK) was down 3.2%, although stock in Lilly may also have been responding to news … Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop … Subscribe to Premium to view Fair Value for XFOR, 2021 expected to be a year of key value-driving catalysts as company advances multiple clinical programs with lead candidate mavorixafor Company anticipates completing full enrollment in WHIM Phase 3 trial in 2021 and presenting clinical data from the ongoing Phase 1b Waldenström’s trial throughout the year Conference call today at 8:30 a.m. See X4 Pharmaceuticals Inc real time stock price, historical quotes and price charts. About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. Every day, we strive to advance our pipeline of innovative medicines to treat rare diseases. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 1053189. Strengthened Leadership Team: During the Fourth Quarter of 2020: Diego Cadavid, M.D., joined as Chief Medical Officer, bringing more than 20 years of industry experience and having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases.Art Taveras, Ph.D., joined as Chief Scientific Officer with more than 30 years of experience leading small molecule research and development programs focused on cancer, dysregulated immune disorders, neurodegeneration, and metabolic diseases.Alison Lawton was appointed to the company’s Board of Directors, bringing more than 30 years of experience across a full spectrum of drug development and commercial roles and having previously served on X4’s corporate advisory board and as consulting Chief Operating Officer. On Monday, Intec Pharma closed at $0.55—81.61% lower than the previous close. The stock was plunging 82.39% to $2.46 in premarket trading Tuesday. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Invest in X4 Pharmaceuticals Inc stock … as Chief Medical Officer: Apr-12-19 09:29AM: X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants: Apr-11-19 04:00PM: X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock … Research and Development Expenses were $12.3 million and $41.9 million for the fourth quarter and full year ended December 31, 2020, respectively, as compared to $7.1 million and $30.2 million for the comparable periods in 2019, respectively. Stock analysis for X4 Pharmaceuticals Inc (XFOR:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 23 2019, Published 9:50 a.m. However, I could not be prouder of our accomplishments, as we remained steadfast in our commitment to advance our lead candidate, mavorixafor, in a number of rare disease indications,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. Net losses include $1.4 million and $5.4 million of certain non-cash expenses for the fourth quarter and full year ended December 31, 2020, respectively. The Boston-based company said it had a loss of 91 cents per share. “On the clinical front, we continue to expect top-line data from our Phase 3 WHIM trial in 2022 and, as our Phase 1b Waldenström’s trial is progressing well, we continue to expect initial data from that study in the first half of 2021, with a more fulsome dataset expected towards the end of 2021. Tonix Pharmaceuticals was the disaster of the day on Tuesday after the company announced that it will stop development of its fibromyalgia treatment after it failed in a late-stage trial. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. George Budwell … Our grit drives solutions for patients. Stifel analyst, Stephen Willey, lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $19.00 (from $20.00) after the company reported a 4Q20 GAAP net loss of $18.4M, or … Following the completion of the call, a webcast replay of the conference call will be available on the website. Teva stock closed at $9.70 on May 29, a 10.8% drop from last Friday’s close. Company profile page for X4 Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information